Some brand drug makers are lobbying to change Senate drug pricing legislation to shift a portion of their share of seniors’ retail drug costs from the catastrophic phase of Medicare Part D to the initial coverage phase, according to sources familiar with the lobbying efforts. Another change being considered would let seniors pay the $3,100 out-of-pocket cap over the year, even when they hit that cap early in the year. The Senate Finance Committee passed in July a bill to...